Results 221 to 230 of about 2,197,203 (280)

Collective Anti‐Mattering: Belief That One's Group Is Being Disregarded Fuels Collective Action and Authoritarian Leadership Support Among Both Advantaged and Disadvantaged Groups

open access: yesEuropean Journal of Social Psychology, EarlyView.
ABSTRACT Groups are motivated not only by resources and status, but also by whether they matter to others. We introduce collective anti‐mattering, the belief that one's group does not count in the eyes of outgroups or society, and examine its emotional and political consequences.
Nassim Tabri   +2 more
wiley   +1 more source

Incidence and impact of respiratory tract infections on outcomes in patients with status epilepticus: A 20‐year longitudinal observation

open access: yesEpilepsia, EarlyView.
Abstract Objective This study was undertaken to identify the incidence of respiratory tract infections (RTIs) in a large cohort of adult patients with status epilepticus (SE) and to characterize their associations with clinical features and outcome determinants.
Sebastian Berger   +8 more
wiley   +1 more source

How to report neurotechnology and artificial intelligence studies in epilepsy: Peer‐review‐inspired recommendations

open access: yesEpilepsia Open, EarlyView.
Abstract Objective The integration of neurotechnology and artificial intelligence (AI) in epilepsy research has led to significant advancements in diagnosis, monitoring, and treatment. However, the impact of these innovations is often diminished by inadequate and inaccurate reporting, limiting their reproducibility and implementation.
Pedro F. Viana   +6 more
wiley   +1 more source

Early Cessation of Adjuvant Anti‐PD‐1 Therapy in Stage III and IV Melanoma

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT One year of adjuvant anti‐PD‐1 has improved disease‐free survival in Stage III melanoma. It is unknown whether shorter treatment duration affects outcomes. Real‐world data may help clarify this. In this retrospective observational study, patients with resected Stage III/IV melanoma receiving adjuvant anti‐PD‐1 in the Netherlands from 2018 to ...
Manja Bloem   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy